Nexus Clinical Research (India) Limited, a active public limited company, was established on 22 November 2005 in Navi Mumbai, Maharashtra, India. Engaging in pharma contract r&d within the professional, scientific and technical sector, it holds CIN: U99999MH2005PLC157715. Registered under ROC Roc Mumbai. it is unlisted. It has an authorized capital of ₹0.50 M and a paid-up capital of ₹0.50 M.
Formerly known as Nexus Clinical Research Private Limited, Nexus Clinical Research (India) Private Limited. It upholds a compliant status. Its leadership includes Meghna Amit Bhatt (Director), Amit Bhatt (Director), Amol Jagahnathrao Ghate (Additional Director). Past directors included Amit Bhatt, Tej Nath Bhat. It holds ₹3.16 Cr open charges and no settled loans. Its latest AGM occurred on 30 September 2024, with the balance sheet filed on 31 March 2024. It is based at Anuj Plot No. 45, 1St Floor, Mumbai-Pune Highway Sector-13, Nerul(E), Navi Mumbai, Maharashtra, 400706.
U99999MH2005PLC157715
157715
22 November 2005
₹0.50 M
₹0.50 M
Roc Mumbai
Unlisted
Active
Explore comprehensive insights into Nexus Clinical Research (India) Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Meghna Amit Bhatt | Director | 01 Dec 2005 | Current |
| Amit Bhatt | Director | 15 Dec 2018 | Current |
| Amol Jagahnathrao Ghate | Additional Director | 04 Jul 2017 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 03 Jul 2017 | Past |
| Pramod Abcsdd | Director | 15 Dec 2018 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Nexus Clinical Research (India) Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 37.47% increase in profit. The company's net worth observed a substantial decline by a decrease of 14.7%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Nexus Clinical Research (India) had a promoter holding of 99.79% and a public holding of 0.21%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹31,601,246.00
₹0
| Date | Lender | Amount | Status |
|---|---|---|---|
| 11 Sep 2018 | Others | ₹2.11 Cr | Open |
| 27 May 2015 | Dewan Housing Finance Corporation Limited | ₹1.05 Cr | Open |
Explore comprehensive loan charge details -
Unlock and access historical data on people associated with Nexus Clinical Research (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Gain comprehensive insights into the Deals and Valuation data of Nexus Clinical Research (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nexus Clinical Research (India)'s trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Nexus Clinical Research (India) Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records. was recorded as a recent event.
Nexus Clinical Research (India) Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai. was recorded as a recent event.
Amit Bhatt was appointed as a Director was appointed as a Director on 15 Dec 2018 & has been associated with this company since 6 years 11 months . was recorded as a recent event.
A charge with Others amounted to Rs. 21.05 M with Charge ID 100203864 was registered on 11 Sep 2018. was recorded as a recent event.
Amol Jagahnathrao Ghate was appointed as a Additional Director was appointed as a Additional Director on 04 Jul 2017 & has been associated with this company since 8 years 4 months . was recorded as a recent event.
Progress on A charge with Dewan Housing Finance Corporation Limited amounted to Rs. 10.55 M with Charge ID 10582815 was registered on 27 May 2015. was documented.
The CIN of Nexus Clinical Research (India) Limited is U99999MH2005PLC157715.
Nexus Clinical Research (India) Limited is headquartered at Anuj Plot No. 45, 1St Floor, Mumbai-Pune Highway Sector-13, Nerul(E), Navi Mumbai, Maharashtra, 400706.
Nexus Clinical Research (India) Limited was incorporated on 22 November 2005.
The current directors of Nexus Clinical Research (India) Limited are
The primary industry of Nexus Clinical Research (India) Limited is Professional, Scientific And Technical.
Nexus Clinical Research (India) Limited is unlisted.
The authorized capital of Nexus Clinical Research (India) Limited is ₹0.50 M, and the paid-up capital is ₹0.50 M.
The compliance status of Nexus Clinical Research (India) Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX